生长抑素受体靶向诊疗在嗅神经母细胞瘤中的应用
本文报告了5例晚期嗅神经母细胞瘤(ENB)患者接受生长抑素受体(SSTR)靶向分子影像与治疗的结果。所有患者SSTR-PET/CT均为阳性,肽受体放射性核素治疗(PRRT)后部分缓解3/5(60%),中位无进展生存期29周,安全性可接受。
要点
- 5例ENB患者SSTR-PET/CT均阳性,病灶SUVmax 24.3±12.8,靶本比19.8±9.7,图像对比良好。
- PRRT中位4周期(范围2-6),每周期中位7.7 GBq,3/5(60%)部分缓解,中位PFS 29周。
- 未观察到白细胞和血小板CTCAE 3/4级毒性,1例(20%)出现可逆性3级贫血。
核心结论
- SSTR靶向PET在ENB中提供高图像对比,提示对该肿瘤类型有良好读出能力;PRRT可行且安全性可接受,使SSTR靶向诊疗成为晚期疾病的潜在治疗选择。
研究设计与样本
- 5例ENB患者(Kadish D期5/5即100%;Hyams 2级2/5即40%,3级2/5即40%,未确定1/5即20%)接受SSTR靶向PET/CT,并基于影像进行PRRT及剂量学分析。
- 记录基线及末次治疗后的肾毒性(eGFR)和血液毒性(血红蛋白、白细胞、血小板),按CTCAE v5.0判定不良事件,并评估疗效和PFS。
主要发现
- 5例患者SSTR-PET/CT均评为阳性;病灶水平共识别32个SSTR摄取病灶,中位肿瘤体积11.7±10.8,SUVmax 24.3±12.8,靶本比19.8±9.7。
- PRRT中位4周期(范围2-6),每例每周期中位7.7 GBq;肿瘤病灶剂量达11.8 Gy。
- 疗效:部分缓解3/5(60%),疾病稳定1/5(20%),疾病进展1/5(20%);中位PFS 29周。
- 安全性:白细胞和血小板无CTCAE 3/4级毒性,肾功能无显著CTCAE事件;1例(20%)出现可逆性3级贫血。
临床怎么用
- 作者认为SSTR靶向诊疗是晚期ENB的潜在治疗选择(原文结论表述为potential treatment option)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: We aim to report on somatostatin receptor (SSTR)-targeted molecular imaging and therapy in patients with advanced esthesioneuroblastoma (ENB). PATIENTS AND METHODS: Five patients with ENB [Kadish stage D in 5/5 (100%); Hyams grade 2 in 2/5 (40%), grade 3 in 2/5 (40%), undetermined in 1/5 (20%)] underwent SSTR-directed PET/CT. We quantified SSTR-avid tumor volume (TV), maximum SUV (SUV max ), and target-to-background ratios (TBR). Based on imaging, peptide receptor radionuclide therapy (PRRT) along with dosimetry was also conducted. We recorded nephrotoxicity and hematotoxicity, including estimated glomerular filtration rate (eGFR), hemoglobin, leukocytes, and thrombocytes at baseline and after the last treatment cycle. We determined adverse events following Common Terminology Criteria for Adverse Events (CTCAE) v5.0. Response and progression-free survival (PFS) was also evaluated. RESULTS: All 5 patients were rated positive on SSTR-PET/CT. On a lesion-based level, we identified 32 SSTR-avid tumor sites with a median TV of 11.7±10.8 and SUV max of 24.3±12.8. TBR was 19.8±9.7, indicating excellent image contrast. After median 4 (range, 2-6) cycles with a median of 7.7 GBq per cycle per patient, we observed no CTCAE grade 3 or 4 toxicity for leukocytes and thrombocytes and no significant CTCAE events for renal function. One patient (20%), however, developed reversible grade 3 anemia. Up to 11.8 Gy in tumor lesions were achieved. Partial response was recorded in 3/5 (60%), stable disease in 1/5 (20%), and progressive disease in 1/5 (20%). The median PFS was 29 weeks. CONCLUSIONS: SSTR-directed PET provided high image contrast in ENB, suggesting good read-out capabilities in this tumor type. PRRT was also feasible, along with an acceptable safety profile, thereby rendering SSTR-targeted theranostics a potential treatment option in advanced disease.
引用
- Zhi Y, Serfling SE, Groener D, et al. Somatostatin Receptor-Directed Theranostics in Esthesioneuroblastoma. Clin Nucl Med. 2025. PMID: 40025672. doi:10.1097/RLU.0000000000005717
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。